CBO 012
Alternative Names: CBO-012Latest Information Update: 23 Nov 2022
At a glance
- Originator Caliway Biopharmaceuticals
- Class Anti-inflammatories; Antirheumatics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Osteoarthritis
Most Recent Events
- 03 Nov 2022 Preclinical trials in Osteoarthritis in Taiwan (unspecified route) before November 2022 (Caliway Biopharmaceuticals pipeline, November 2022)
- 03 Nov 2022 Caliway Biopharmaceuticals plans to submit IND application to initiate phase I/IIa trial in Osteoarthritis in 2025 (Caliway Biopharmaceuticals pipeline, November 2022)
- 03 Nov 2022 Caliway Biopharmaceuticals plans a phase I/IIa trial in Osteoarthritis (Caliway Biopharmaceuticals pipeline, November 2022)